Status:
TERMINATED
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Lead Sponsor:
Danish Oncological Lung Cancer Group
Conditions:
Extensive Disease
First-Line
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
Detailed Description
Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer ...
Eligibility Criteria
Inclusion
- Histologically confirmed SCLC
- Extensive stage
- No prior chemotherapy
- WHO PS 0-3
- Adequate organ function (liver, kidney)
- Adequate hematology (bone marrow)
- Informed consent
Exclusion
- PS 4
- Inadequate organ function
- Uncontrolled infection
- Concomitant major medical contraindications
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT00812266
Start Date
January 1 2006
End Date
January 1 2015
Last Update
January 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. Oncology, Rigshospitalet
Copenhagen, Denmark